Abstract |
The expression of CD56 antigen in acute promyelocytic leukemia (APL) blasts has been associated with short remission duration and extramedullary relapse. We investigated the clinical significance of CD56 expression in a large series of patients with APL treated with all-trans retinoic acid and anthracycline-based regimens. Between 1996 and 2009, 651 APL patients with available data on CD56 expression were included in 3 subsequent trials (PETHEMA LPA96 and LPA99 and PETHEMA/HOVON LPA2005). Seventy-two patients (11%) were CD56(+) (expression of CD56 in ≥ 20% leukemic promyelocytes). CD56(+) APL was significantly associated with high white blood cell counts; low albumin levels; BCR3 isoform; and the coexpression of CD2, CD34, CD7, HLA-DR, CD15, and CD117 antigens. For CD56(+) APL, the 5-year relapse rate was 22%, compared with a 10% relapse rate for CD56(-) APL (P = .006). In the multivariate analysis, CD56 expression retained the statistical significance together with the relapse-risk score. CD56(+) APL also showed a greater risk of extramedullary relapse (P < .001). In summary, CD56 expression is associated with the coexpression of immaturity-associated and T-cell antigens and is an independent adverse prognostic factor for relapse in patients with APL treated with all-trans-retinoic acid plus idarubicin-derived regimens. This marker may be considered for implementing risk-adapted therapeutic strategies in APL. The LPA2005 trial is registered at http://www.clinicaltrials.gov as NCT00408278.
|
Authors | Pau Montesinos, Chelo Rayón, Edo Vellenga, Salut Brunet, José González, Marcos González, Aleksandra Holowiecka, Jordi Esteve, Juan Bergua, José D González, Concha Rivas, Mar Tormo, Vicente Rubio, Javier Bueno, Félix Manso, Gustavo Milone, Javier de la Serna, Inmaculada Pérez, Manuel Pérez-Encinas, Isabel Krsnik, Josep M Ribera, Lourdes Escoda, Bob Lowenberg, Miguel A Sanz, PETHEMA, HOVON Groups |
Journal | Blood
(Blood)
Vol. 117
Issue 6
Pg. 1799-805
(Feb 10 2011)
ISSN: 1528-0020 [Electronic] United States |
PMID | 21148082
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anthracyclines
- CD56 Antigen
- NCAM1 protein, human
- Tretinoin
|
Topics |
- Adolescent
- Adult
- Anthracyclines
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- CD56 Antigen
(blood)
- Female
- Humans
- Leukemia, Promyelocytic, Acute
(blood, drug therapy, immunology)
- Male
- Middle Aged
- Prognosis
- Recurrence
- Risk Factors
- Tretinoin
(administration & dosage)
- Young Adult
|